Cromolyn inhibits the secretion of inflammatory cytokines by human microglia (HMC3)

• Published in: Scientific reports Vol. 11; no. 1; pp. 8054 - 11
• Main Authors: Wang, Yi-Jun, Monteagudo, Alina, Downey, Matthew A., Ashton-Rickardt, Philip G., Elmaleh, David R.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 13.04.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/250/127; 631/250/2504/342/1952; 631/250/256; 631/250/371; 631/250/98; 692/699/375/132; 692/699/375/364; 692/699/375/365; 692/699/375/365/1283; Alzheimer Disease - drug therapy; Alzheimer Disease - metabolism; Alzheimer's disease; Asthma; CCL3 protein; CCL4 protein; Cell Line; Chemokines; Chemokines - metabolism; Cromolyn Sodium - pharmacology; CXCL10 protein; Cytokines; Cytokines - metabolism; Dosage; Humanities and Social Sciences; Humans; Ibuprofen; IL-1β; Inflammation; Inflammation Mediators - metabolism; Interleukin 6; Interleukin 8; Microglia; Microglia - drug effects; Microglia - metabolism; Monocyte chemoattractant protein 1; multidisciplinary; Neurodegenerative diseases; Science; Science (multidisciplinary); Tumor necrosis factor-α; γ-Interferon

Cromolyn is a known mast cell stabilizer and is approved for treatment of asthma and for other allergic indications. Cromolyn, in a new redesigned dry powder formulation, is being tested in a pivotal clinical trial in combination with low dose ibuprofen to treat early Alzheimer’s Disease (AD) subjec...